Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.38 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737335 | 1.00 | HRH3 (0.55) | HRH3LMNAALDH1A1MAPTPOLB | |
| SCHEMBL12504205 | 1.00 | HRH3 (0.55) | HRH3LMNAALDH1A1MAPTPOLB | |
| SCHEMBL2102597 | 1.00 | HRH3 (0.55) | HRH3LMNAALDH1A1MAPTPOLB | |
| SCHEMBL246069 | 1.00 | — | — | |
| SCHEMBL19837631 | 0.97 | HRH3 (0.52) | HRH3LMNAALDH1A1MAPTPOLB | |
| Water SCHEMBL29029809 | 0.97 | HRH3 (0.52) | HRH3LMNAALDH1A1MAPTPOLB | |
| SCHEMBL11716 | 0.97 | — | — | |
| SCHEMBL787670 | 0.90 | — | — | |
| SCHEMBL5087744 | 0.88 | POLB (0.46) | HRH3LMNAALDH1A1MAPTPOLB | |
| SCHEMBL387453 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024120454-A1 | BIS-PHOSPHATIDYL AMINE COMPOUNDS CONTAINING MULTIPLE TERTIARY AMINO STRUCTURES, AND COMPOSITION AND USE THEREOF | 北京大学 | 2024-06-13 | — | — | WO | claimed |
| CN-118146262-A | Bi-phosphatidyl amide compound containing multiple tertiary amino structures, composition and application thereof | 北京大学 | 2024-06-07 | — | — | CN | claimed |
| EP-3862354-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2021-08-11 | — | — | EP | claimed |
| EP-2824105-B1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2021-03-31 | — | — | EP | claimed |
| EP-2824105-A1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2015-01-14 | — | — | EP | claimed |
| US-8530493-B2 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2013-09-10 | — | — | US | claimed |
| US-20110027226-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) | 4SC AG (DE) | 2011-02-03 | — | — | US | claimed |
| US-20090246169-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | NYCOMED GMBH (DE) | 2009-10-01 | — | — | US | claimed |
| US-20090233902-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2009-09-17 | — | — | US | claimed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | claimed |
| WO-2005070900-A1 | N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | claimed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | claimed |
| US-6846827-B1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-01-25 | — | — | US | claimed |
| EP-1226126-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | claimed |
| EP-1226126-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-31 | — | — | EP | claimed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| WO-2001027089-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110027226-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) | KIF5A, KIF5C, KIF5B | HRH3 2340/4885LMNA 2432/4885ALDH1A1 3349/4885 |
| US-20090233902-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | KIF5A, KIF5C, KIF5B | HRH3 1780/4885LMNA 3053/4885ALDH1A1 2483/4885 |
| US-20020107235-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | HRH3 1748/4885LMNA 4623/4885ALDH1A1 1651/4885 |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | HRH3 680/4885LMNA 1123/4885ALDH1A1 1137/4885 |
| US-20090246169-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | KIF5A, KIF5C, KIF5B | HRH3 1780/4885LMNA 3053/4885ALDH1A1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.